Asthma drug reduces risk of COVID-19 hospitalization by 90%, study suggests

Inhaled budesonide, a drug commonly used to treat asthma, reduced the risk of urgent care or hospitalization for COVID-19 patients by 90 percent, according to a recent University of Oxford study.   

Researchers analyzed data from a 28-day clinical study of 146 patients, half of which took inhaled budesonide — sold as AstraZeneca's Pulmicort — twice a day.

The drug cut the risk of urgent care or hospitalization by 90 percent within the study period and was also tied to a "quicker resolution of fever, symptoms, and fewer persistent symptoms."

The study findings were published Feb. 4 on the medRxiv preprint server. The study has yet to be peer reviewed. 

More articles on patient safety and outcomes:
Roche arthritis drug reduces COVID-19 death risk, Oxford research suggests
FDA updates guidance on ventilator splitting
Joint Commission issues alert on providing equitable care during pandemic


© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars